In nuclear medicine, radioactive material is used for the diagnostic and therapeutic treatment of disease, including cancer. The demand for radiotherapeutics is expected to increase significantly over the next few decades. The aim of this project is to optimise the production of novel medical radionuclides in a research reactor.
This project seeks to develop a new method in treating cancer by coupling nuclear medicine with Creo Medical’s sophisticated medical microwave technologies. Nuclear medicine is a well-established subset of radiology that implants radioactive material into a patient for the diagnosis and treatment of disease.
This project would aim to investigate the feasibility of producing tritium on the industrial scale that would be required to support the deployment of fusion power so that FPPs would not have to breed their own tritium. The longer-term vision is for the UK to create a tritium production industry that could service both the UK and global FPP industry need. In the shorter term it is recognised that STEP, other UK and international small spherical Tokamak reactors and private fusion endeavours will need tritium supplies for their early year.